Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer.

BMC cancer - 25 May 2018

Hirooka Yoshiki, Kasuya Hideki, Ishikawa Takuya, Kawashima Hiroki, Ohno Eizaburo, Villalobos Itzel B, Naoe Yoshinori, Ichinose Toru, Koyama Nobuto, Tanaka Maki, Kodera Yasuhiro, Goto Hidemi

Abstract excerpt

BACKGROUND: Prognosis of pancreatic cancer is poor with a 5-year survival rate of only 7%. Although several new chemotherapy treatments have shown promising results, all patients will eventually progress, and we need to develop newer chemotherapy treatments to improve response rates and overall survival (OS). HF10 is a spontaneously mutated oncolytic virus derived from a herpes simplex virus-1, and it has...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Deoxycytidine
Share to Endosonography

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erlotinib Hydrochloride

Share to Gemcitabine

Share to Herpesvirus 1, Human

Share to Oncolytic Virotherapy

Share to Oncolytic Viruses

Share to Progression-Free Survival

Source

Open in PubMed Open full text

Identifiers

PMID: 29801474
DOI: 10.1186/s12885-018-4453-z
PMCID: PMC5970460

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer.PMID 29801474Read ↗

Phase I Dose-escalation Clinical Trial of HF10 Oncolytic Herpes Virus in 17 Japanese Patients with Advanced Cancer.Semantic proximity Read ↗

Optimizing Pancreatic Cancer Therapy: The Promise of Immune Stimulatory Oncolytic VirusesSemantic proximity Read ↗

Clinical experiment of mutant herpes simplex virus HF10 therapy for cancer.Semantic proximity Read ↗

Effective treatment of pancreatic cancer xenografts with a conditionally replicating virus derived from type 2 herpes simplex virus.Semantic proximity Read ↗

Oncolytic virotherapy for pancreatic cancer.Semantic proximity Read ↗

Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial.Semantic proximity Read ↗

Preclinical development of non-viral gene therapy for patients with advanced pancreatic cancerSemantic proximity Read ↗

First-in-man Phase 1 Clinical Trial of Gene Therapy for Advanced Pancreatic Cancer: Safety, Biodistribution, and Preliminary Clinical FindingsSemantic proximity Read ↗

Ultrasound–guided percutaneous laser ablation for pancreatic cancer: a new treatment optionSemantic proximity Read ↗

Effects of tumor selective replication-competent herpes viruses in combination with gemcitabine on pancreatic cancer.Semantic proximity Read ↗

Phase I trial of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for the treatment of metastatic pancreatic cancerSemantic proximity Read ↗

Oncolytic herpes simplex virus-1 mutant expressing green fluorescent protein can detect and treat peritoneal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.